Thursday, February 28, 2008

Researchers Engineer First System Of Human Nerve Cell Tissue
Researchers at the University of Pennsylvania School of Medicine have demonstrated that living human nerve cells can be engineered into a network that could one day be used for transplants to repair damaged to the nervous system

MS Society Offers Another Line Of Support, UK
The MS Society is reaching out to more people affected by multiple sclerosis (MS) than ever before thanks to the launch of an email Helpline facility.For some people, sending an email is easier than making a call and those in need of information and emotional support can now take advantage of a new way of contacting the award-winning MS Society Helpline.

MS Societies In UK And Australia Provide International Research Opportunities
Worldwide collaborative links between researchers investigating the debilitating neurological condition multiple sclerosis (MS) have been strengthened thanks to the introduction of the first UK and Australian Fellowship Exchange programme.

Protein Screen Offers Clues To Future Treatment Options, UK
A study published in this month shows how proteins might be important in the underlying processes occurring in Multiple Sclerosis (MS).This relatively novel work is screening and identifying 27 Feb 2008

Tysabri May Cause Liver Damage, Health Officials Say
HealthDay via Yahoo! News Wed, 27 Feb 2008 2:03 PM PST
WEDNESDAY, Feb. 27 (HealthDay News) -- The controversial multiple sclerosis drug Tysabri can start causing liver damage within six days of the first dose, U.S. health officials said Wednesday.

Biogen and Elan warn of liver injury from Tysabri
Reuters via Yahoo! News Wed, 27 Feb 2008 12:26 PM PST
Biogen Idec Inc and Elan Corp Plc have warned doctors of significant liver injury suffered by some patients taking the multiple sclerosis drug Tysabri, U.S. regulators said on Wednesday.

Biogen, Elan warn of liver injury from Tysabri
Reuters via Yahoo! News Wed, 27 Feb 2008 10:56 AM PST
Biogen Idec Inc and Elan Corp Plc are warning doctors about reports of "significant" liver injury suffered by patients taking their Tysabri multiple sclerosis drug, the U.S. Food and Drug Administration said on Wednesday.

Tysabri May Cause Liver Damage, Health Officials Say
KOLD News 13 Tuscon Wed, 27 Feb 2008 2:42 PM PST
By Steven Reinberg , HealthDay Reporter WEDNESDAY, Feb. 27 (HealthDay News) -- The controversial multiple sclerosis drug Tysabri can start causing liver damage...

MS Societies In UK And Australia Provide International Research Opportunities
Medical News Today Wed, 27 Feb 2008 6:05 AM PST
Worldwide collaborative links between researchers investigating the debilitating neurological condition multiple sclerosis (MS) have been strengthened thanks to the introduction of the first UK and Australian Fellowship Exchange programme.

MS Society Offers Another Line Of Support, UK
Medical News Today Wed, 27 Feb 2008 6:05 AM PST
The MS Society is reaching out to more people affected by multiple sclerosis (MS) than ever before thanks to the launch of an email Helpline facility.For some people, sending an email is easier than making a call and those in need of information and emotional support can now take advantage of a new way of contacting the award-winning MS Society Helpline.

Protein Screen Offers Clues To Future Treatment Options, UK
Medical News Today Wed, 27 Feb 2008 5:07 AM PST
A study published in this month shows how proteins might be important in the underlying processes occurring in Multiple Sclerosis (MS).This relatively novel work is screening and identifying proteins involved in MS, particularly in the different types of lesion in the central nervous system of people with MS.

Designer Diagnostics Begins Marketing First Ever Environmental Test Kit For The Detection Of Nontuberculous Mycobacteria
Medical News Today Wed, 27 Feb 2008 4:05 AM PST
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that its wholly-owned medical devices subsidiary, Designer Diagnostics, has started marketing the first-ever environmental test kit for the detection of Nontuberculous Mycobacteria (NTM) in water and soil.

Adult stem cells used to treat MS
KING5 Seattle Tue, 26 Feb 2008 6:12 PM PST
Adult stem cells are being used to successfully treat patients with heart disease, even autoimmune disorders. One man with multiple sclerosis says his symptoms are completely gone.

Multiple sclerosis stem cells

HealthFirst-Adult stem cell therapy
ABC12.com - Flint,MI,USA
HealthFirst reporter Leslie LoBue says one patient diagnosed with multiple sclerosis says his symptoms are gone. Barry Goudy was diagnosed with multiple ...
See all stories on this topic

OTCPicks.com Daily Market Movers Digest Midday Report
TransWorldNews (press release) - Monroe,GA,USA
Its principal stem cell products are solutions containing allo stem cell biological solutions, either adult stem cells, and stem cells that are extracted ...
See all stories on this topic

Study: Stem cells have great potential
abc7.com - Los Angeles,CA,USA
At least one patient with multiple sclerosis went into remission after treatment with adult stem cells. Experts think other diseases like diabetes will ...
See all stories on this topic

Adult Stem Cells May Treat Many Diseases
WebMD - USA
Since the late 1990s, adult stem cell therapy has been used experimentally to treat multiple sclerosis (MS), type 1 diabetes, rheumatoid arthritis, ...
See all stories on this topic

Adult stem cells used to treat MS
KING5.com - Seattle,WA,USA
After Barry Goudy was diagnosed with multiple sclerosis in 1995, he began losing feeling in his left leg, then his vision started to go. ...
See all stories on this topic

Adult Stem Cells Show They Can Conquer More Than Cancer
WRAL.com - Raleigh,NC,USA
Now it's being used to treat heart trouble and other diseases – and it even helped a man with multiple sclerosis. Barry Goudy learned he had multiple ...
See all stories on this topic

Stopping MS

Stopping MS
WFTV 9 Orlando Thu, 28 Feb 2008 12:17 PM PST
About 400,000 Americans have multiple sclerosis, a debilitating disease that causes difficult walking and an inability to control breathing. But doctors are testing a new drug that could stop the disease in its tracks. VIDEO: Stopping MS
HEALTH NOTES
Richmond Times-Dispatch Wed, 27 Feb 2008 9:24 PM PST
"Diabetic Dining Made Easy" will be offered Wednesday, and April 2 from 9:30 to 11:30 a.m. and again April 7 from 7 to 9 p.m. at VCU Women's Health Care, 9000 Stony Point Parkway. The cost is $35. Elizabeth Horn of Disability Benefits Assistance will speak at the Hanover Multiple Sclerosis Support Group meeting today at 7 p.m. at Commonwealth Wholesale Inc., 10085 Leadbetter Place, Ashland.


Multiple Sclerosis, Cannabinoids, and Cognition
Journal of Neuropsychiatry (subscription) - USA
79 This review also reported that chronic progressive multiple sclerosis patients display maximal deficits on frontal-executive tasks, whereas patients with ...
See all stories on this topic


Tysabri

Thursday Newspaper Review - Irish Business News and International ...
FinFacts Ireland - Ireland
A total of 21100 multiple sclerosis patients were being treated with Tysabri early last month. The company recently received permission from the FDA to ...
See all stories on this topic

Tysabri May Cause Significant Liver Injury
Medscape (subscription) - USA
February 27, 2008 — Significant liver injury has been reported in some patients receiving treatment with natalizumab (Tysabri, Biogen Idec, Inc), ...
See all stories on this topic

Biogen warns of liver damage risk from Tysabri Mass High Tech: The ...
Bizjournals.com - Charlotte,NC,USA
Last month, the FDA approved the Tysabri as a treatment for a chronic inflammatory condition called Crohn's disease. The treatment was previously approved ...
See all stories on this topic

Wednesday's Health Winners & Losers
TheStreet.com - USA
Biogen IdecBIIB and ElanELN lost ground after the FDA posted a letter to doctors warning about the effects of the companies' multiple sclerosis drug Tysabri ...
See all stories on this topic

Biogen's Tysabri May Cause Liver Injury, US Says (Update3)
Bloomberg - USA
s multiple sclerosis medicine Tysabri may harm the liver within six days of the first dose, US regulators said, urging doctors to warn patients about the ...
See all stories on this topic

Hepatoxicity Warning Added to Natalizumab (Tysabri) Label
MedPage Today - Little Falls,NJ,USA
27 -- The multiple sclerosis drug natalizumab (Tysabri) may cause clinically significant liver injury, which can occur as early as six days after the ...
See all stories on this topic

Shares of Biogen and Elan fall on reports of liver damage in ...
International Herald Tribune - France
The companies issued a warning to doctors that signs of liver injury appeared in patients as early as six days after first taking Tysabri. ...
See all stories on this topic

Biogen's Tysabri May Cause Liver Injury, US Says (Update2)
Bloomberg - USA
s multiple sclerosis medicine Tysabri may cause significant liver injury within six days of the first dose, US regulators said. Patients should stop taking ...
See all stories on this topic

Biogen, Elan warn of liver injury from Tysabri
Reuters - USA
Signs of liver damage occurred in some patients as early as six days after their first dose of Tysabri, the companies said in their letter. ...
See all stories on this topic

Biogen, Elan warn of liver injury risks w/Tysabri in letter posted ...
CNNMoney.com - USA
'In some patients, liver injury recurred upon rechallenge, providing evidence that Tysabri caused the injury.' Any patients exhibiting signs of jaundice or ...
See all stories on this topic

Elan's credit rating outlook raised to positive by Moody's ...
CNNMoney.com - USA
Moody's Analyst Michael Levesque said other positive developments for the drugmaker include the recent US Food and Drug Administration approval of Tysabri ...
See all stories on this topic


Acorda Therapeutics Q4 Loss Widens On Expenses
RTT News - Williamsville,NY,USA
We also initiated investments for the commercialization of Fampridine-SR, if approved.” As of December 31, 2007, Acorda held cash, cash equivalents and ...
See all stories on this topic

Acorda Therapeutics Announces Acquisition of Aminopyridine and Pre ...
FOXBusiness - USA
Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. ...
See all stories on this topic

Novartis premium threatened by sparse new drugs
Guardian Unlimited - UK
It lacks any obvious billion-dollar seller candidates with the possible exception of FTY720 for multiple sclerosis. Chairman and Chief Executive Daniel ...
See all stories on this topic

Cytomegalovirus Infection in Paediatric Haemopoietic Stem Cell ...
Irish Medical Journal - Dublin,Ireland
The pan T-cell antibody Campath was incorporated into conditioning regimens for patients undergoing unrelated transplants. Three patients had ex vivo T-cell ...
See all stories on this topic

NeoStem Reports Positive Stem Cell Industry Research Trends From ...
Earthtimes - London,UK
... multiple sclerosis and arthritis. More than 500 of these are for autologous use, meaning the stem cells come from your own body for your own use. ...
See all stories on this topic

Acute and Chronic Lyme Disease: Controversies for Neuropsychiatry
Journal of Neuropsychiatry (subscription) - USA
Small areas of abnormality in the white matter that are hyperintense on T2W MRI, similar to those seen in multiple sclerosis, may be present. ...
See all stories on this topic


Chef With Multiple Sclerosis Uses Culinary Skills And Passion For Golf To Support National MS Society Michigan Chapter
Medical News Today Thu, 28 Feb 2008 2:05 AM PST
The first thing that Chef Bill Pikarski wants you to know is that Multiple Sclerosis is not a death sentence. Nor does it mean that you cannot live a full, rewarding life. After being diagnosed with MS in August of 2002, Pikarski went through a period of depression and denial. Two things helped change his outlook: The National Multiple Sclerosis Society and golf.

Tuesday, February 26, 2008

Yale Scientists Create Artificial “Cells” that Boost the Immune Response to Cancer




http://www.yale.edu/opa/newsr/08-02-26-03.all.html

New Haven, Conn. — Using artificial cell-like particles, Yale biomedical engineers have devised a rapid and efficient way to produce a 45-fold enhancement of T cell activation and expansion, an immune response important for a patient’s ability to fight cancer and infectious diseases, according to an advance on line report in Molecular Therapy.

The artificial cells, developed by Tarek Fahmy, assistant professor of biomedical engineering at Yale and his graduate student Erin Steenblock, are made of a material commonly used for biodegradable sutures. The authors say that the new method is the first “off-the-shelf” antigen-presenting artificial cell that can be tuned to target a specific disease or infection.

“This procedure is likely to make it to the clinic rapidly,” said senior author Fahmy. “All of the materials we use are natural, biodegradable already have FDA approval.”

Cancer, viral infections and autoimmune diseases have responded to immunotherapy that boosts a patient’s own antigen-specific T cells. In those previous procedures, a patient’s immune cells were harvested and then exposed to cells that stimulate the activation and proliferation of antigen-specific T-cells. The “boosted” immune cells were then infused back into the patient to attack the disease.

Limitations of these procedures include costly and tedious custom isolation of cells for individual patients and the risk of adverse reaction to foreign cells, according to the Yale researchers. They also pointed to difficulty in obtaining and maintaining sufficient numbers of activated T-cells for effective therapeutic response.

In the new system, the outer surface of each particle is covered in universal adaptor molecules that serve as attachment points for antigens — molecules that activate the patient’s T-cells to recognize and fight off the targeted disease — and for stimulatory molecules. Inside of each particle, there are slowly released cytokines that further stimulate the activated T-cells to proliferate to as much as 45 times their original number.

“Our process introduces several important improvements,” said lead author Steenblock. “First, the universal surface adaptors allow us to add a span of targeting antigen and co-stimulatory molecules. We can also create a sustained release of encapsulated cytokines. These enhancements mimic the natural binding and signaling events that lead to T-cell proliferation in the body. It also causes a fast and effective stimulation of the patient’s T-cells — particularly T-cells of the cytotoxic type important for eradicating cancer.”

“Safe and efficient T-cell stimulation and proliferation in response to specific antigens is a goal of immunotherapy against infectious disease and cancer,” said Fahmy. “Our ability to manipulate this response so rapidly and naturally with an “off the shelf” reproducible biomaterial is a big step forward.”

Fahmy was recently awarded a five-year National Science Foundation (NSF) Career Award for work on this process and ways of engineering biomaterials to manipulate immune responses to fight cancer and other diseases. His approach incorporates signals important for T-cell stimulation in biocompatible polymer particulates, and integrates all the signals needed for efficient T-cell stimulation.

According to the NSF, devices as such these offer ease and flexibility in targeting different types of T-cells, and is expected to lead to state of the art improvements in the preparation of a new generation of therapeutic systems.

The US Department of Homeland Security provided partial funding for this work.

Citation: Molecular Therapy (advance online February 26, 2008)



FOR IMMEDIATE RELEASE: February 26, 2008

http://www.yale.edu/opa/newsr/08-02-26-03.all.html



Tarek Fahmy and Erin Steenblock Tarek Fahmy and Erin Steenblock monitor T-cell activation as tool for fighting cancer




Stimulatory particles Stimulatory particles (red) bound to activated T-cells (blue) as seen by fluorescence microscopy. Scale bar = 10 μm


Monday, February 25, 2008

Adult stem cells offer hope for gravely ill

Adult stem cells offer hope for gravely ill
Louisville Courier-Journal - Louisville,KY,USA
Researchers also are looking at using them to treat autoimmune disorders such as multiple sclerosis. Adult stem cells are different from the controversial ...
See all stories on this topic

‘The best friends in the world’
La Crosse Tribune - La Crosse,WI,USA
In June, as doctors prepared Greg for a stem cell transplant, they discovered he had leukemia. That meant another 50 days in the hospital for more heavy ...
See all stories on this topic

Euthanasia: 'We should not be made to suffer like this'
Daily Telegraph Sun, 24 Feb 2008 4:22 PM PST
As Luxembourg joins Holland and Belgium in legalising euthanasia, Val McKay, terminally ill with multiple sclerosis, tells Jocasta Shakespeare why the law in Britain should change.

Biogen Fourth-Quarter Net Rises 85 Percent on Tysabri (Update1)
Bloomberg - USA
Profit excluding certain costs beat analysts' estimates by 9 cents a share Revenue rose 26 percent from a year earlier to $893 million as sales of Tysabri ...
See all stories on this topic

Elan mulls technology unit spin-off: report
Reuters - USA
The company is considering splitting its biopharmaceuticals arm, which markets its flagship multiple sclerosis drug Tysabri, from EDT, the paper said. ...
See all stories on this topic

Montel Williams Quit Because Of MS
Starpulse.com - Branford,CT,USA
Talk show host Montel Williams has quit his long-running TV show because the multiple sclerosis he suffers from is beginning to take a grip. ...
See all stories on this topic

Sunday, February 17, 2008

Hoping on healing

Hoping on healing
Glens Falls Post-Star - Glens Falls,NY,USA
Rosary is a 28-year-old single mother with a form of multiple sclerosis called "relapsing and remitting," in which a crippling attack can take place at any ...
See all stories on this topic

Brain drug target discovery in MS
BBC News Sun, 17 Feb 2008 2:35 PM PST
US researchers find two potential targets for treating multiple sclerosis after studying proteins in the brain.
New targets found for MS treatments
The Scotsman Sun, 17 Feb 2008 4:25 PM PST
SCIENTISTS have found two new potential treatment targets for multiple sclerosis.

Tasty ways to raise money and awareness; MS Global Dinner Parties ...
St. Catharines Standard - St. Catharines,Ontario,Canada
Ladies and gentleman, students, staff: my speech is on multiple sclerosis." That's right, MS. How I can recall the exact opening lines of my Grade 4 ...
See all stories on this topic

Mercury is dangerous
The Coloradoan - Fort Collins,CO,USA
Colorado is ground zero for mercury in soil and also has the highest incidence of new cases of multiple sclerosis in the country, which can be related to ...
See all stories on this topic

Q Therapeutics Announces Series B Investment
News & Observer - Raleigh,NC,USA
Q-Cells are applicable to a wide range of demyelinating diseases, including multiple sclerosis (MS), transverse myelitis, cerebral palsy, spinal cord injury ...
See all stories on this topic

Acorda Therapeutics Q4 Loss Widens On Expenses [ACOR]
RTT News - Williamsville,NY,USA
We also initiated investments for the commercialization of Fampridine-SR, if approved.” As of December 31, 2007, Acorda held cash, cash equivalents and ...
See all stories on this topic

‘I’m not afraid to die, but I worry about how and where it’ll happen’
ic Wales - United Kingdom
Siaron West has been looking after husband Peter, who suffers from primary progressive multiple sclerosis, at their home in Heath, Cardiff. ...
See all stories on this topic

Thursday, February 14, 2008

Lawyer argues killer's health at risk if jailed

Raising Funds For MS Research One Party At A Time, Canada
Medical News Today (press release) - UK
They'll be joined by others around the world hosting parties in support of research to end multiple sclerosis. "We believe that the MS Global Dinner Party ...
See all stories on this topic

ZymoGenetics, Inc. Q4 2007 Earnings Call Transcript
Seeking Alpha - New York,NY,USA
We also expect to begin two multiple sclerosis studies in the early part of this year. One is the Phase 2 study in relapsing-remitting disease and the other ...
See all stories on this topic

Active Biotech Year-End Report January-December 2007
PharmaLive.com (press release) - Newtown,PA,USA
Comments from President and CEO Sven Andréasson: "During the year, the US and European regulatory authorities approved laquinimod for Phase III and ...
See all stories on this topic

Experimental MS drug shows promise, offers new window on disease
Science Centric - Sofia,Sofia Town,Bulgaria
The study, reported in the 14 February 2008 issue of the 'New England Journal of Medicine,' showed that the drug, rituximab, dramatically reduced the number ...
See all stories on this topic

Cancer drug slows multiple sclerosis
Reuters via Yahoo! News Thu, 14 Feb 2008 12:26 PM PST
Two infusions of the cancer drug Rituxan given 2 weeks apart slowed the progression of multiple sclerosis for nearly 1 year, researchers reported on Wednesday.

CORRECTION: Cancer drug slows multiple sclerosis progression
Reuters via Yahoo! News Wed, 13 Feb 2008 7:28 PM PST
Two infusions of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly a year, researchers reported on Wednesday.

Drug that targets different part of immune system may help multiple sclerosis patients
Minneapolis-St. Paul Star Tribune Wed, 13 Feb 2008 6:24 PM PST
An experimental treatment for multiple sclerosis that targets a portion of the immune system not previously subjected to therapy reduced damaging lesions of the nervous system by 91 percent and relapses of the disease by 58 percent, researchers reported today in the New England Journal of Medicine.

Marijuana slows thinking in MS patients
UPI Thu, 14 Feb 2008 3:55 PM PST
Smoking marijuana may make cognitive and emotional problems worse in multiple sclerosis patients, a Canadian study finds.

MS therapy shows promise in test
Los Angeles Times Thu, 14 Feb 2008 0:16 AM PST
A cancer drug greatly reduces brain lesions and relapses in patients with the most common form of the disabling disease. An experimental treatment for multiple sclerosis that targets a portion of the immune system not previously subjected to therapy reduced damaging lesions of the nervous system by 91% and relapses of the disease by 58%, researchers report today.

Pot may impair mental function in MS patients
CTV.ca Thu, 14 Feb 2008 5:22 AM PST
Patients with multiple sclerosis who choose to smoke marijuana to help relieve some of their symptoms may be harming their cognitive abilities, finds new Canadian research.

Smoking pot may slow MS sufferers' thoughts
New Scientist Thu, 14 Feb 2008 3:12 AM PST
People with multiple sclerosis who smoke marijuana may process thoughts more slowly than people with MS who do not, hints a preliminary study

Promising Experimental MS Drug Offers New Window On Disease
Medical News Today Thu, 14 Feb 2008 5:17 AM PST
A drug therapy currently used to treat non-Hodgkin's lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial.

Smoking Marijuana Impairs Cognitive Function In MS Patients
Medical News Today Thu, 14 Feb 2008 1:15 AM PST
People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology®, the medical journal of the American Academy of Neurology.

Lawyer argues killer's health at risk if jailed
ABC via Yahoo!7 News Wed, 13 Feb 2008 8:13 PM PST
A Supreme Court judge is being urged not to jail a young man who has been convicted of manslaughter, with lawyers arguing it could worsen his multiple sclerosis.

Wednesday's Winners & Losers: Nortel Networks
TheStreet.com - USA
Acorda will use the proceeds to finish its second late-stage clinical trial on multiple sclerosis treatment Fampridine-SR and for a regulatory filing and ...
See all stories on this topic

Wednesday's Health Winners & Losers
TheStreet.com - USA
Acorda will use the proceeds to finish its second late-stage clinical trial on multiple sclerosis treatment Fampridine-SR and for a regulatory filing and ...
See all stories on this topic

Acorda Therapeutics Q4 Loss Widens On Expenses [ACOR]
RTT News - Williamsville,NY,USA
We also initiated investments for the commercialization of Fampridine-SR, if approved.” As of December 31, 2007, Acorda held cash, cash equivalents and ...
See all stories on this topic

Genentech, Biogen's Rituxan Cuts Relapses of Multiple Sclerosis
Bloomberg - USA
s Campath has shown a similar effect in clinical trials, he said. ``The real strength is the magnitude of effect on the MRI, the relapse rate, ...
See all stories on this topic

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
PR Newswire (press release) - New York,NY,USA
Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks ...
See all stories on this topic

Raising Funds For MS Research One Party At A Time, Canada
Medical News Today (press release) - UK
They'll be joined by others around the world hosting parties in support of research to end multiple sclerosis. "We believe that the MS Global Dinner Party ...
See all stories on this topic

ZymoGenetics, Inc. Q4 2007 Earnings Call Transcript
Seeking Alpha - New York,NY,USA
We also expect to begin two multiple sclerosis studies in the early part of this year. One is the Phase 2 study in relapsing-remitting disease and the other ...
See all stories on this topic

Active Biotech Year-End Report January-December 2007
PharmaLive.com (press release) - Newtown,PA,USA
Comments from President and CEO Sven Andréasson: "During the year, the US and European regulatory authorities approved laquinimod for Phase III and ...
See all stories on this topic

Experimental MS drug shows promise, offers new window on disease
Science Centric - Sofia,Sofia Town,Bulgaria
The study, reported in the 14 February 2008 issue of the 'New England Journal of Medicine,' showed that the drug, rituximab, dramatically reduced the number ...
See all stories on this topic

Cancer drug slows multiple sclerosis
Reuters via Yahoo! News Thu, 14 Feb 2008 12:26 PM PST
Two infusions of the cancer drug Rituxan given 2 weeks apart slowed the progression of multiple sclerosis for nearly 1 year, researchers reported on Wednesday.

CORRECTION: Cancer drug slows multiple sclerosis progression
Reuters via Yahoo! News Wed, 13 Feb 2008 7:28 PM PST
Two infusions of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly a year, researchers reported on Wednesday.

Drug that targets different part of immune system may help multiple sclerosis patients
Minneapolis-St. Paul Star Tribune Wed, 13 Feb 2008 6:24 PM PST
An experimental treatment for multiple sclerosis that targets a portion of the immune system not previously subjected to therapy reduced damaging lesions of the nervous system by 91 percent and relapses of the disease by 58 percent, researchers reported today in the New England Journal of Medicine.

Marijuana slows thinking in MS patients
UPI Thu, 14 Feb 2008 3:55 PM PST
Smoking marijuana may make cognitive and emotional problems worse in multiple sclerosis patients, a Canadian study finds.

MS therapy shows promise in test
Los Angeles Times Thu, 14 Feb 2008 0:16 AM PST
A cancer drug greatly reduces brain lesions and relapses in patients with the most common form of the disabling disease. An experimental treatment for multiple sclerosis that targets a portion of the immune system not previously subjected to therapy reduced damaging lesions of the nervous system by 91% and relapses of the disease by 58%, researchers report today.

Pot may impair mental function in MS patients
CTV.ca Thu, 14 Feb 2008 5:22 AM PST
Patients with multiple sclerosis who choose to smoke marijuana to help relieve some of their symptoms may be harming their cognitive abilities, finds new Canadian research.

Smoking pot may slow MS sufferers' thoughts
New Scientist Thu, 14 Feb 2008 3:12 AM PST
People with multiple sclerosis who smoke marijuana may process thoughts more slowly than people with MS who do not, hints a preliminary study

Promising Experimental MS Drug Offers New Window On Disease
Medical News Today Thu, 14 Feb 2008 5:17 AM PST
A drug therapy currently used to treat non-Hodgkin's lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial.

Smoking Marijuana Impairs Cognitive Function In MS Patients
Medical News Today Thu, 14 Feb 2008 1:15 AM PST
People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology®, the medical journal of the American Academy of Neurology.

Lawyer argues killer's health at risk if jailed
ABC via Yahoo!7 News Wed, 13 Feb 2008 8:13 PM PST
A Supreme Court judge is being urged not to jail a young man who has been convicted of manslaughter, with lawyers arguing it could worsen his multiple sclerosis.

Wednesday's Winners & Losers: Nortel Networks
TheStreet.com - USA
Acorda will use the proceeds to finish its second late-stage clinical trial on multiple sclerosis treatment Fampridine-SR and for a regulatory filing and ...
See all stories on this topic

Wednesday's Health Winners & Losers
TheStreet.com - USA
Acorda will use the proceeds to finish its second late-stage clinical trial on multiple sclerosis treatment Fampridine-SR and for a regulatory filing and ...
See all stories on this topic

Acorda Therapeutics Q4 Loss Widens On Expenses [ACOR]
RTT News - Williamsville,NY,USA
We also initiated investments for the commercialization of Fampridine-SR, if approved.” As of December 31, 2007, Acorda held cash, cash equivalents and ...
See all stories on this topic

Genentech, Biogen's Rituxan Cuts Relapses of Multiple Sclerosis
Bloomberg - USA
s Campath has shown a similar effect in clinical trials, he said. ``The real strength is the magnitude of effect on the MRI, the relapse rate, ...
See all stories on this topic

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
PR Newswire (press release) - New York,NY,USA
Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks ...
See all stories on this topic

Rituximab Effective Against MS in Phase II Trial

Rituximab Effective Against MS in Phase II Trial
MedPage Today - Little Falls,NJ,USA
Genentech is now conducting a phase II/III trial of rituximab in primary progressive MS. In an accompanying editorial, Henry McFarland, MD, of the National ...
See all stories on this topic

Scientists Research Delivering Drugs Straight To Brain, UK
Scientists at the University of Portsmouth have won nearly half a million pounds to try and develop a way of allowing drugs to be delivered straight to the brain. The grant allows a team to spend the next three years trying to unlock the blood brain barrier to allow drugs to be targeted at diseases including cancer.

MONTEL QUIT BECAUSE OF MULTIPLE SCLEROSIS
PR-Inside.com (Pressemitteilung) - Wien,Austria
LATEST: Talk show host MONTEL WILLIAMS has quit his long-running US TV programme because the multiple sclerosis he suffers from is beginning to take a grip. ...
See all stories on this topic

Experimental MS drug shows promise, offers new window on disease
UCSF News Office - San Francisco,CA,USA
... to evaluate the safety and efficacy of rituximab in primary-progressive MS (PPMS), a severe form of the disease with significant unmet medical need. ...
See all stories on this topic

Cancer drug Rituxan may help treat MS
San Francisco Chronicle - CA, USA
The drug co-developers have already begun a clinical trial of Rituxan in a more severe form of the disease, primary progressive multiple sclerosis. ...
See all stories on this topic

Cannabis Associated with Cognitive Impairment in MS
MedPage Today - Little Falls,NJ,USA
MS disease course was relapsing-remitting in 82 participants (58.6%), secondary progressive in 49 (35%), and primary progressive in nine (6.4%). ...

See all stories on this topic Vital MS drug given green light in Ulster
Belfast Telegraph
Tue, 12 Feb 2008 0:48 AM PST
Fresh hope is being offered to hundreds of Ulster multiple sclerosis sufferers today after the Government ruled that a promising new drug which could slow progression will be available within months.

Chronic Pain May Harm the Brain

Cancer drug slows multiple sclerosis progression
Reuters via Yahoo! UK & Ireland News Wed, 13 Feb 2008 2:18 PM PST
Two shots of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly a year, researchers reported on Wednesday.

Marijuana Use Among MS Patients Raises Risk for Cognitive, Mood Problems
HealthDay via Yahoo! News Wed, 13 Feb 2008 1:02 PM PST
WEDNESDAY, Feb. 13 (HealthDay News) -- Multiple sclerosis patients who smoke marijuana in search of symptom relief are more likely to suffer cognitive shortfalls and mood disorders, new Canadian research suggests.

Cancer Drug Works Against MS in Early Trial
HealthDay via Yahoo! News Wed, 13 Feb 2008 2:01 PM PST
WEDNESDAY, Feb. 13 (HealthDay News) -- A drug originally designed to combat cancer that is now being used to treat autoimmune diseases such as rheumatoid arthritis and lupus might also work against a common form of multiple sclerosis.

Rituximab Shows Promise for MS
WebMD Wed, 13 Feb 2008 2:55 PM PST
Multiple sclerosis patients treated with the cancer drug Rituxan showed rapid and dramatic improvement in brain lesions and had fewer relapses than expected.

Smoking marijuana impairs cognitive function in MS patients
EurekAlert! Wed, 13 Feb 2008 1:09 PM PST
ST. PAUL, Minn. – People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology®, the medical journal of the American Academy of Neurology.

Pot Use May Hamper Thinking in MS
WebMD Wed, 13 Feb 2008 1:55 PM PST
Among multiple sclerosis patients, marijuana users may have slower reaction times on mental skills tests, a Canadian study shows.

Experimental MS drug shows promise, offers new window on disease
EurekAlert! Wed, 13 Feb 2008 2:14 PM PST
A drug therapy currently used to treat non-Hodgkin’s lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial.

Smoking pot to ease MS symptoms may impair mental acuity, study suggests
The Canadian Press via Yahoo! Canada News Wed, 13 Feb 2008 2:53 PM PST
TORONTO - Some people with multiple sclerosis have turned to street marijuana in a bid to ease pain and other symptoms of the disabling neurological disorder, but new research suggests smoking pot may further harm already vulnerable cognitive abilities.

MS sufferers who smoke pot have greater cognitive problems: study
CBC Wed, 13 Feb 2008 2:17 PM PST
Though many multiple sclerosis sufferers turn to marijuana for relief of their symptoms, a new study finds that smoking the drug can actually cause problems with emotional responses and memory.

Wednesday, February 13, 2008

Scientists Research Delivering Drugs Straight To Brain, UK
Scientists at the University of Portsmouth have won nearly half a million pounds to try and develop a way of allowing drugs to be delivered straight to the brain. The grant allows a team to spend the next three years trying to unlock the blood brain barrier to allow drugs to be targeted at diseases including cancer.

MONTEL QUIT BECAUSE OF MULTIPLE SCLEROSIS
PR-Inside.com (Pressemitteilung) - Wien,Austria
LATEST: Talk show host MONTEL WILLIAMS has quit his long-running US TV programme because the multiple sclerosis he suffers from is beginning to take a grip. ...
See all stories on this topic

Rituximab Effective Against MS in Phase II Trial
MedPage Today - Little Falls,NJ,USA
Genentech is now conducting a phase II/III trial of rituximab in primary progressive MS. In an accompanying editorial, Henry McFarland, MD, of the National ...
See all stories on this topic

Experimental MS drug shows promise, offers new window on disease
UCSF News Office - San Francisco,CA,USA
... to evaluate the safety and efficacy of rituximab in primary-progressive MS (PPMS), a severe form of the disease with significant unmet medical need. ...
See all stories on this topic

Cancer drug Rituxan may help treat MS
San Francisco Chronicle - CA, USA

The drug co-developers have already begun a clinical trial of Rituxan in a more severe form of the disease, primary progressive multiple sclerosis. ...
See all stories on this topic

Cannabis Associated with Cognitive Impairment in MS
MedPage Today - Little Falls,NJ,USA
MS disease course was relapsing-remitting in 82 participants (58.6%), secondary progressive in 49 (35%), and primary progressive in nine (6.4%). ...

See all stories on this topic
Vital MS drug given green light in Ulster
Belfast Telegraph
Tue, 12 Feb 2008 0:48 AM PST
Fresh hope is being offered to hundreds of Ulster multiple sclerosis sufferers today after the Government ruled that a promising new drug which could slow progression will be available within months.

Chronic Pain May Harm the Brain

Cancer drug slows multiple sclerosis progression
Reuters via Yahoo! UK & Ireland News Wed, 13 Feb 2008 2:18 PM PST
Two shots of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly a year, researchers reported on Wednesday.

Marijuana Use Among MS Patients Raises Risk for Cognitive, Mood Problems
HealthDay via Yahoo! News Wed, 13 Feb 2008 1:02 PM PST
WEDNESDAY, Feb. 13 (HealthDay News) -- Multiple sclerosis patients who smoke marijuana in search of symptom relief are more likely to suffer cognitive shortfalls and mood disorders, new Canadian research suggests.

Cancer Drug Works Against MS in Early Trial
HealthDay via Yahoo! News Wed, 13 Feb 2008 2:01 PM PST
WEDNESDAY, Feb. 13 (HealthDay News) -- A drug originally designed to combat cancer that is now being used to treat autoimmune diseases such as rheumatoid arthritis and lupus might also work against a common form of multiple sclerosis.

Rituximab Shows Promise for MS
WebMD Wed, 13 Feb 2008 2:55 PM PST
Multiple sclerosis patients treated with the cancer drug Rituxan showed rapid and dramatic improvement in brain lesions and had fewer relapses than expected.

Smoking marijuana impairs cognitive function in MS patients
EurekAlert! Wed, 13 Feb 2008 1:09 PM PST
ST. PAUL, Minn. – People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology®, the medical journal of the American Academy of Neurology.

Pot Use May Hamper Thinking in MS
WebMD Wed, 13 Feb 2008 1:55 PM PST
Among multiple sclerosis patients, marijuana users may have slower reaction times on mental skills tests, a Canadian study shows.

Experimental MS drug shows promise, offers new window on disease
EurekAlert! Wed, 13 Feb 2008 2:14 PM PST
A drug therapy currently used to treat non-Hodgkin’s lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial.

Smoking pot to ease MS symptoms may impair mental acuity, study suggests
The Canadian Press via Yahoo! Canada News Wed, 13 Feb 2008 2:53 PM PST
TORONTO - Some people with multiple sclerosis have turned to street marijuana in a bid to ease pain and other symptoms of the disabling neurological disorder, but new research suggests smoking pot may further harm already vulnerable cognitive abilities.

MS sufferers who smoke pot have greater cognitive problems: study
CBC Wed, 13 Feb 2008 2:17 PM PST
Though many multiple sclerosis sufferers turn to marijuana for relief of their symptoms, a new study finds that smoking the drug can actually cause problems with emotional responses and memory.

Tuesday, February 12, 2008

Saint Francis ‘Robot’ Offers MS Patients Hope

Saint Francis ‘Robot’ Offers MS Patients Hope
Hartford Business - USA
Cummings is doing some of the work, building back muscles that his multiple sclerosis helped to atrophy. But the machine, called a Lokomat, is helping too. ...
See all stories on this topic

Antisense Therapeutics licenses ATL1102 to Teva
Trading Markets (press release) - Los Angeles,CA,USA
ANP also has the potential to receive payments related to the continued clinical development of ATL1102 for MS upon certain future development milestones, ...
See all stories on this topic

Scientists Find New Receptor for HIV
New York Times - United States
One candidate is a drug, Tysabri or natalizumab, that is marketed for treatment of multiple sclerosis, Dr. Fauci said. Biogen/Elan makes Tysabri. ...
See all stories on this topic

Biogen net income soars as Tysabri continues to grow
Pharma Times (subscription) - London,UK
Best of all, however, was the performance of the new MS drug Tysabri (natalizumab), which is partnered with Elan and only returned to the market in July ...
See all stories on this topic

NORTH INDIAN RIVER COUNTY LIBRARY: Author to give talk at library ...
TCPalm - West Palm Beach,FL,USA
Montel Williams gives us tools for "Living Well: 21 Days to Transform Your Life, Supercharge Your Health and Feel Spectacular." With specific directions for ...
See all stories on this topic

Acorda Therapeutics Reports Fourth Quarter and Full Year 2007 ...
Business Wire (press release) - San Francisco,CA,USA
We also initiated investments for the commercialization of Fampridine-SR, if approved,” said Ron Cohen, MD, President and Chief Executive Officer of Acorda ...
See all stories on this topic

Acorda reports Q4 loss
Business in the Burbs - White Plains,NY,USA
It is trying to develop Fampridine-SR, another drug for treatment of multiple sclerosis. This entry was posted by Allan Drury on Monday, February 11th, ...
See all stories on this topic

Therapeutic vaccine approach for Parkinson's disease
NTV - Kearney,NE,USA
Cop-1 has been used effectively in patients with chronic neuroinflammatory disease such as relapsing remitting multiple sclerosis for more than a decade. ...
See all stories on this topic

Myelin Repair Foundation Launches First-Of-A-Kind Drug Discovery Advisory Group
The Myelin Repair Foundation (MRF), a U.S.-based not-for profit medical research foundation focused on accelerating the rate of target identification and validation to speed drug discovery and development, has launched a first-of-a-kind Drug Discovery Advisory Group (DDAG).
'New aspirin' vitamin D isn't understood
UPI Fri, 08 Feb 2008 10:40 AM PST
Vitamin D may guard against heart disease, osteoporosis, multiple sclerosis and cancer but its effects aren't completely understood, a Canadian researcher says.

Drugmaker Biogen Idec 4Q Profit Surges
The Associated Press -
On a conference call with analysts Wednesday, Biogen Idec Chief Executive James Mullen said no buyers emerged because risks surrounding the MS drug Tysabri ...
See all stories on this topic

Billy Talent Drummer Acts As Driving Force Behind MS Scholarship Program, Canada
The Multiple Sclerosis Society of Canada announced that for the second year in a row, scholarship applications are now available for youth directly impacted by MS. The drummer of one of Canada's hottest punk rock bands, Billy Talent, is the driving force behind the program.

Billy Talent Drummer Acts As Driving Force Behind MS Scholarship Program, Canada
Medical News Today Fri, 08 Feb 2008 5:15 AM PST
The Multiple Sclerosis Society of Canada announced that for the second year in a row, scholarship applications are now available for youth directly impacted by MS. The drummer of one of Canada's hottest punk rock bands, Billy Talent, is the driving force behind the program.

Vitamin D for cancer
News-Medical-Net Thu, 07 Feb 2008 5:24 PM PST
It sounds too good to be true … a little inexpensive pill that could block the development of some cancers, strengthen bones, prevent multiple sclerosis and alleviate winter depression.

Friday, February 08, 2008

Progress after Adult Stem Cell Therapy Offers New Hope to Iowa Spinal Cord Injury Patient

Rich Welsh, a 28 year-old insurance agent from Klemme, Iowa who suffered a spinal cord injury after an automobile accident in 1999, is now on the road to recovery after stem cell therapy in Cologne, Germany.

Cologne, Germany (PRWEB) February 7, 2008 -- Rich Welsh, a 28 year-old insurance agent from Klemme, Iowa who suffered a spinal cord injury after an automobile accident in 1999, is now on the road to recovery after stem cell therapy in Cologne, Germany.

-------------------------------------------------------------------------

Mr. Welsh became a C-5 quadriplegic after his unfortunate accident. Since then, he has received adult stem cell therapy twice; the latest time in mid-2007. Following these treatments, Mr. Welsh can now feel hot and cold sensations in his stomach and his muscle spasms have decreased significantly. He has also regained the ability to sweat. However, his most notable gain has occurred since his second treatment - return of sexual function. "Since that treatment I have started regaining my sexual function. No more blue pill," joked Welsh. When asked what advice he would give to those considering this treatment, Mr. Welsh replied, "If you happen to come across the chance of having autologous stem cell therapy that may improve your quality of life - do not let it pass you by."
---------------------------------------------------------------------------------------

Since that treatment I have started regaining my sexual function. No more blue pill
The spinal cord injury treatment at XCell-Center employs (autologous) stem cells that come from the patient's own bone marrow. After the stem cells are separated from the bone marrow, they are implanted into the spinal canal under local anesthesia. This procedure is very safe and takes about 30 minutes.

About the XCell-Center
The XCell-Center is the first privately-owned center in Europe to specialize in regenerative medicine using autologous bone marrow adult stem cell therapy. Newly completed in early 2007, the XCell-Center is a fully licensed clinic featuring the latest medical equipment and technology. Its specialized medical team of German physicians includes: neurologists, endocrinologists, cardiologists, radiologists, hematologists, and pharmacologists. The XCell-Center works in accordance with German law and European guidelines.

The XCell-Center currently treats Diabetes and its complications (Erectile Dysfunction and Peripheral Artery Disease), Stroke, Spinal Cord Injuries, Ischemic Heart Disease and degenerative diseases such as Multiple Sclerosis, Parkinson's and Alzheimer's.

The XCell-Center has submitted its SCIDIM I and II trials to its investigational review board. In these trials, diabetes (type I and II) patients are being treated with their own stem cells and compared with a control group receiving traditional therapy. The findings will be presented at different international scientific meetings. Also later this year, another clinical trial for stroke patients will commence. These trials are only open to German residents.

--------------------------------------------------------------------------------------------------
For more information on Stem Cell Therapy:
XCell-Center Website: http://www.xcell-center.com

XCell-Center GmbH
at the Institute for Regenerative Medicine

Custodisstrasse 3-17
Cologne, Germany 50679

Phone: 1-866-680-8202 (USA Toll-Free)
(+49) 0221-802-5095 (Germany)

Fax: (+49) 0221-2921-2550 (Germany)
1-713-583-9322 (USA)

###


http://www.prweb.com/releases/2008/2/prweb680883.htm

Sunshine vitamin' may help prevent cancer
New Kerala Thu, 07 Feb 2008 10:28 AM PST
Washington, Feb 7 : A researcher at Dalhousie University has claimed that a vitamin D pill could block the development of some cancers, strengthen bones, prevent multiple sclerosis and alleviate winter depression.

More Brain Research Suggests "Use It Or Lose It", Australia
Queensland Brain Institute (QBI) scientists have found another important clue to why nerve cells die in neurodegenerative diseases, based on studies of the developing brain.

Biogen Rests Rumors
Motley Fool - USA
No discussion of a Biogen earnings call would be complete without a mention of its multiple sclerosis treatment Tysabri. Tysabri worldwide sales by Biogen ...
See all stories on this topic

Globe promotes Hall to VP of human resources
Boston Globe - United States
(Jenn Abelson) Two multiple sclerosis patients developed skin cancer after taking Tysabri, a drug from Biogen Idec Inc. and Elan Corp. that suppresses the ...
See all stories on this topic

Ahead of the Bell: Biogen Idec
Forbes - NY,USA
Biogen late Wednesday posted quarterly profit and sales far above analyst estimates, driven by growing revenue from multiple sclerosis drugs Tysabri and ...
See all stories on this topic

Letter In Medical Journal Suggests MS Drug, Melanoma Linked
CNNMoney.com - USA
PLC's (ELN) MS drug Tysabri. The letter says the cases suggest that the drug may lead to development and progression of the skin cancer in high-risk ...
See all stories on this topic

Multiple Sclerosis Drug May Cause Skin Cancer
MedIndia - Chennai,India
Tysabri is a monoclonal antibody that helps treat autoimmune disorders such as Multiple Sclerosis and Crohn's disease. It has proved effective in slowing ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Sheldon Brown dies
Bicycling - USA
Doctors, at first stumped, eventually diagnosed him with primary-progressive multiple sclerosis in August 2007. Brown is survived by his wife, Harriet, ...
See all stories on this topic

Acorda Therapeutics To Sell 2.66 Mln Common Shares In Public ...
RTT News - Williamsville,NY,USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic

Thursday, February 07, 2008

Multiple Sclerosis Drug May Be Linked to Melanoma

Multiple Sclerosis Drug May Be Linked to Melanoma
HealthDay via Yahoo! News Wed, 06 Feb 2008 2:23 PM PST
WEDNESDAY, Feb. 6 (HealthDay News) -- Almost immediately after a 46-year-old woman with multiple sclerosis received her first dose of the drug Tysabri, a mole that had been on her shoulder for years suddenly took on a dangerous new character.


Diabetes Study Partially Halted After Deaths

Multiple Sclerosis Drug May Be Linked to Melanoma
KOLD News 13 Tuscon Wed, 06 Feb 2008 2:57 PM PST
By Amanda Gardner , HealthDay Reporter WEDNESDAY, Feb. 6 (HealthDay News) -- Almost immediately after a 46-year-old woman with multiple sclerosis received her first...

Multiple Sclerosis Drug May Be Linked to Melanoma
Health Scout Wed, 06 Feb 2008 4:54 PM PST
Doctors report 2 cases of the deadly skin cancer developing in patients taking Tysabri.

Tysabri May Be Linked to Melanoma
WebMD Wed, 06 Feb 2008 2:53 PM PST
Two multiple sclerosis patients developed malignant melanoma -- a deadly form of skin cancer -- soon after starting treatment with Tysabri, researdhers report.

A Ray of Sunshine in the Fight Against Cancer
Newswise Wed, 06 Feb 2008 12:19 PM PST
Dalhousie University epidemiologist Dr. Louise Parker, says a vitamin D pill could block the development of some cancers, strengthen bones, prevent multiple sclerosis and alleviate winter depression.

The Brain Is Harmed By Chronic Pain
People with unrelenting pain don't only suffer from the non-stop sensation of throbbing pain. They also have trouble sleeping, are often depressed, anxious and even have difficulty making simple decisions.

NeuroDigm's Model Reveals The Reversal Of Chronic Pain
Mary Hannaman MD, president of NeuroDigm Co. in Fort Worth, Texas has confirmed that a recombinant human erythropoietin, epoetin alfa, can reverse neural changes that cause chronic pain behavior.

Multiple Sclerosis Drug May Be Linked to Melanoma
U.S. News & World Report - Washington,DC,USA
6 (HealthDay News) -- Almost immediately after a 46-year-old woman with multiple sclerosis received her first dose of the drug Tysabri, a mole that had been ...
See all stories on this topic

Casa Grande Regional Medical Center
Casa Grande Valley Newspapers - Casa Grande,AZ,USA
Primary progressive MS: is characterized by a slow but basically steady decline without distinct periods of relapse and remission. ...
See all stories on this topic

------------------------------------------

Market Update - MS drug Tysabri sales
Sydney Morning Herald - Sydney,New South Wales,Australia
quarter). In addition they reported that the number of patients that were on commercial and clinical which is reflected in the growing sales of the drug. ...
See all stories on this topic

Tysabri May Be Linked to Melanoma
WebMD - USA
6, 2008 -- Two multiple sclerosis patients developed malignant melanoma -- a deadly form of skin cancer -- soon after starting treatment with Tysabri. ...
See all stories on this topic

Biogen Idec chief takes counterjab at Icahn
Boston Globe - United States
"This [Biogen Idec] is one of them" Mullen said Biogen Idec didn't draw any solid offers because of worries about its multiple sclerosis drug, Tysabri, ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Biogen Fourth-Quarter Net Rises 85 Percent on Tysabri (Update2)
Bloomberg - USA
Revenue rose 26 percent from a year earlier to $893 million as worldwide sales of Tysabri quadrupled. Biogen said it expects 100000 patients will be taking ...
See all stories on this topic

Biogen Idec Reports Full Year and Fourth Quarter 2007 Results
FOXBusiness - USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. -- On a reported basis, ...
See all stories on this topic

Biogen Idec profit beats expectations
Houston Chronicle - United States
The newer MS treatment Tysabri generated revenue of $90 million, up from $18 million in the year-ago quarter. Tysabri had been seen as a potential ...
See all stories on this topic

Biogen Idec Draws "Line In The Sand" With Carl Icahn
CNBC - Englewood Cliffs,NJ,USA
The company beat the Street, sales of Tysabri for multiple sclerosis were higher than expected and the biotech reaffirmed its 2008 financial guidance. ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Hits and Misses: Wednesday's Earnings Reports
FOXBusiness - USA
A newer MS drug, Tysabri, posted sales of $129 million. The drug was removed from the market in early 2005 due to safety concerns, but reintroduced more ...
See all stories on this topic
------------------------------------------------------------------

Wednesday's Health Winners & Losers
TheStreet.com - USA
Proceeds will go to late-stage development and regulatory filing of Fampridine-SR in multiple sclerosis. Also trailing midweek, Edwards LifesciencesEW said ...
See all stories on this topic

Wednesday's Winners & Losers: Riverbed Technology
TheStreet.com - USA
... and are expected to continue to increase in 2008, primarily due to an increase in spending on the Fampridine-SR clinical and preclinical programs. ...
See all stories on this topic

Acorda Therapeutics To Sell 2.66 Mln Common Shares In Public ...
RTT News - Williamsville,NY,USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic

Acorda Therapeutics, Inc. Announces Proposed Public Offering of ...
FOXBusiness - USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic

Acorda Sinks on Forecast Wider 2008 Loss
Houston Chronicle - United States
... after the biotechnology company said it expects a wider 2008 net loss on higher costs for its experimental multiple sclerosis drug, Fampridine-SR. ...
See all stories on this topic

Acorda Therapeutics To Sell 2.66 Mln Common Shares In Public ...
RTT News - Williamsville,NY,USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic

Acorda proposes sale of 2.75M shares
Business in the Burbs - White Plains,NY,USA
Acorda also plans to use the proceeds from the offering to fund further research into its Fampridine-SR drug for treatment of multiple sclerosis. ...
See all stories on this topic

Lloyd Keir, ‘my hero’ - Wheeler’s tribute to his best mate
Dubbo Daily Liberal - Dubbo,New South Wales,Australia
“He was only about 30 when he contracted multiple sclerosis and it’s been a struggle for him and his family ever since - but the problems he had didn’t ...
See all stories on this topic